Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. - Wikidata - awgldk - TriplyDB

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

http://www.wikidata.org/entity/Q43563104

about

Adaptive immunity in the liver Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal Stealth and cunning: hepatitis B and hepatitis C viruses.Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.Immunology of hepatitis B virus and hepatitis C virus infection Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population.Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection Human genes involved in hepatitis B virus infection.Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.Pathogenesis of hepatitis B virus infection Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy Hepatitis B viral load affects prognosis of hepatocellular carcinoma.Strategies to eliminate HBV infection.Combination treatment in HBeAg-negative chronic hepatitis B.Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy.Viral determinants and host immune responses in the pathogenesis of HBV infection.Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy.Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.Therapy of chronic hepatitis B: current challenges and opportunities.Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine Kinetics of phytohemaglutinin-induced IFN-gamma and TNF-alpha expression in peripheral blood mononuclear cells from patients with chronic hepatitis B after liver transplantation High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion The importance and benefits of hepatitis A prevention in chronic liver disease patients.Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study.

P2860

Q26753195-FDBD327D-A246-4EC0-89CF-962FEDBE67F0 Q26828598-5FB8CFC1-40C9-4259-BC4F-E0EA259C2C80 Q26995814-441ADE9C-844B-41AC-A72F-C000883EF209 Q27470232-1D24860E-4E5F-4366-A88B-211516EC658F Q27488200-A0879E30-E854-4548-A401-E754895B7F2C Q28076279-A5E8DE50-A415-4745-A102-E14A96DF16F0 Q28086980-2C29EC40-6476-4896-9EB9-E182CE98661F Q28742762-41E37F6F-80A2-4B8D-A2C8-BFFCB88F6B54 Q29618957-ABB662FB-094F-4776-A1FA-E054B445476B Q33211869-EE493DB0-6B66-4187-A979-E8FE97CDADEC Q33313034-00DA8414-76FB-4A0A-B07B-0B2DD617D4CE Q33370720-85BB4E47-6E09-464B-89F2-6BFCF26D1320 Q33747793-AB3788C7-D32E-4D07-A2B6-425A6BE2D305 Q33787525-4FAAB963-052F-496C-9FF0-A018864C8190 Q33801320-1E015D35-35EE-4B05-926F-7BEBA02C9D41 Q33867509-21A98AAA-B142-4CD4-8273-82DF33DA9AF4 Q33868880-4F4A109A-90AD-4689-BA7F-C08D8C350EF4 Q33925491-A18E1270-AC78-484C-A7BA-30161C166334 Q33948393-AB24C0B8-84B0-41EF-9AA5-52BAA1B0A2D3 Q34151071-A36C840E-C621-42CA-8BEB-797A84AE5615 Q34168459-D4FD2C04-ADB7-4385-89A4-CB2917FA8ECA Q34308129-C24D618F-E515-41C6-82FC-4B0B33874071 Q34391476-9C80CAE2-803F-40D8-9490-636D30AE4811 Q34529159-99B16F5E-26CC-4E53-970B-7D2C6A86543A Q34626075-19E81365-DC21-4820-8F57-4F410B58907B Q34737124-19C08027-FAE4-4B4E-AACE-58B4336FC8FA Q34742036-A017B9E9-5ACE-4211-A469-9EDA8ACD67AB Q34762295-1CF12339-0417-4791-9E67-94799EE4502B Q34778476-64D04E31-D215-4BB9-AB30-6A42B0E41DDF Q34812028-E75571F1-37E6-48CB-B22A-08DCC66895C6 Q34928150-49980CEC-8AF5-4B62-9406-BA11CCAC9620 Q34975716-ADA4C0CF-3F09-4834-9960-55224ABB11C3 Q34996613-423DA148-1895-4DE5-BE19-A839133C64D1 Q35010506-74409AE6-7CEC-49D0-A2DA-BD6ADC53E258 Q35435517-E2E15780-5AD8-4C14-BA4D-7A832E0F621B Q35597143-2790C496-24DB-4B42-A615-05851CB9D786 Q35726960-336B4382-450E-40FB-8E31-B75CFEF6EE05 Q35741969-204923B7-7B6E-4E25-A21E-AE5DF7E04A63 Q35780216-1E6FD5C3-7DFB-43A4-B67A-A96BA4C14285 Q35885358-2BD126AB-4D49-4998-B528-F69BCA2B4C4D

P2860

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

http://www.wikidata.org/entity/Q43563104

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Lamivudine treatment can overc ...... rspectives for immune therapy.

@en

Lamivudine treatment can overc ...... rspectives for immune therapy.

@nl

type

label

Lamivudine treatment can overc ...... rspectives for immune therapy.

@en

Lamivudine treatment can overc ...... rspectives for immune therapy.

@nl

prefLabel

Lamivudine treatment can overc ...... rspectives for immune therapy.

@en

Lamivudine treatment can overc ...... rspectives for immune therapy.

@nl

P1433

Q43563104-91CBB6C6-32E4-4611-BC1C-53643959EF80

P1476

Q43563104-85F8F113-71C5-482D-9007-574EC57BD53E

P2093

Q43563104-3D31D3C9-5E04-43B9-8219-B6A731251DD0

Q43563104-40AD5953-D899-441C-AF88-9D7AC55BE9BC

Q43563104-51ADA70D-537F-403D-9243-1FAB4C092C12

Q43563104-55FD0E04-A673-4163-A085-0E26224603EA

Q43563104-7357156E-3DE9-4737-8E78-9B8D46BE00D6

Q43563104-75104D89-8159-46DE-A1C5-F2FC9BEE5EC4

Q43563104-92A801B0-9A4B-4ED8-BD06-F80BCCF56480

Q43563104-96F94BB2-B3CA-46B8-B604-9D7137F415B7

Q43563104-D8FE9F9E-F1C2-4329-B211-D25901833E6A

P304

Q43563104-0843A62B-4074-42F2-8FB4-4388521968BD

P31

Q43563104-1631555B-8CC2-4B68-B164-BE0903CCBBB0

P356

Q43563104-A778C601-63F6-4553-BDC7-42E7DB2250F5

P407

Q43563104-F028E7E4-A6AD-48DE-8169-E62F6E0E04D0

P433

Q43563104-79B8CC0D-5DD7-423E-9D4D-CC0008F81B35

P478

Q43563104-78434D4F-1C62-4156-95E8-9074EA5D025C

P50

Q43563104-39220CCD-DE4A-43FE-A980-8CFBCA6C216E

Q43563104-6F2C8C95-B3FA-484B-86E2-A64226E42AA2

Q43563104-892C45FA-5E1F-4259-B7A3-223951E17FA3

Q43563104-A61DBED4-D61C-4511-9BC2-1BE8E8466E24

P577

Q43563104-6D10F13B-2ED9-40AB-85C0-26CD0D3F53B0

P5875

Q43563104-97FCE8D1-150A-42D0-BE53-8D652BFCB314

P698

Q43563104-3E2387AD-C6A8-4755-9599-C55BAF6005E4

P921

Q43563104-E98A1958-B77D-4211-850C-7AAE37E85A1B

P356

JHEP.2001.23045

P1433

P1476

Lamivudine treatment can overc ...... erspectives for immune therapy

@en

P2093

Boehme R

http://www.w3.org/2001/XMLSchema#string

Cavalli A

http://www.w3.org/2001/XMLSchema#string

Cavallo C

http://www.w3.org/2001/XMLSchema#string

Fiaccadori F

http://www.w3.org/2001/XMLSchema#string

Ogg GS

http://www.w3.org/2001/XMLSchema#string

Panebianco R

http://www.w3.org/2001/XMLSchema#string

Penna A

http://www.w3.org/2001/XMLSchema#string

Pilli M

http://www.w3.org/2001/XMLSchema#string

Urbani S

http://www.w3.org/2001/XMLSchema#string

P304

963-971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2001.23045

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Bertoletti

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12049542

http://www.w3.org/2001/XMLSchema#string

P698

11283861

http://www.w3.org/2001/XMLSchema#string

P921